CIBC Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $335K | Sell |
5,927
-26
| -0.4% | -$1.52K | ﹤0.01% | 931 |
|
|
2025
Q4 | $354K | Sell |
5,953
-2,248
| -27% | -$122K | ﹤0.01% | 896 |
|
|
2025
Q3 | $444K | Buy |
8,201
+58
| +0.7% | +$3.32K | ﹤0.01% | 802 |
|
|
2025
Q2 | $448K | Buy |
8,143
+53
| +0.7% | +$3.12K | ﹤0.01% | 783 |
|
|
2025
Q1 | $572K | Buy |
8,090
+433
| +6% | +$29.1K | ﹤0.01% | 729 |
|
|
2024
Q4 | $503K | Buy |
7,657
+926
| +14% | +$62K | ﹤0.01% | 753 |
|
|
2024
Q3 | $473K | Buy |
6,731
+359
| +6% | +$30K | ﹤0.01% | 755 |
|
|
2024
Q2 | $525K | Buy |
6,372
+325
| +5% | +$27.1K | ﹤0.01% | 726 |
|
|
2024
Q1 | $528K | Buy |
6,047
+13
| +0.2% | +$1.16K | ﹤0.01% | 728 |
|
|
2023
Q4 | $582K | Sell |
6,034
-445
| -7% | -$39.4K | ﹤0.01% | 702 |
|
|
2023
Q3 | $573K | Buy |
6,479
+155
| +2% | +$13.8K | ﹤0.01% | 702 |
|
|
2023
Q2 | $548K | Buy |
6,324
+4
| +0.1% | +$376 | ﹤0.01% | 714 |
|
|
2023
Q1 | $615K | Buy |
6,320
+311
| +5% | +$32.2K | ﹤0.01% | 707 |
|
|
2022
Q4 | $622K | Sell |
6,009
-2,233
| -27% | -$210K | ﹤0.01% | 711 |
|
|
2022
Q3 | $699K | Buy |
8,242
+22
| +0.3% | +$1.96K | ﹤0.01% | 714 |
|
|
2022
Q2 | $681K | Sell |
8,220
-3,569
| -30% | -$284K | ﹤0.01% | 708 |
|
|
2022
Q1 | $909K | Sell |
11,789
-28,805
| -71% | -$2.41M | ﹤0.01% | 716 |
|
|
2021
Q4 | $3.59M | Buy |
40,594
+920
| +2% | +$75.9K | 0.01% | 429 |
|
|
2021
Q3 | $3.07M | Buy |
39,674
+6,366
| +19% | +$502K | 0.01% | 440 |
|
|
2021
Q2 | $2.78M | Buy |
33,308
+3,476
| +12% | +$276K | 0.01% | 454 |
|
|
2021
Q1 | $2.25M | Buy |
29,832
+23,128
| +345% | +$1.89M | 0.01% | 477 |
|
|
2020
Q4 | $588K | Sell |
6,704
-12,222
| -65% | -$969K | ﹤0.01% | 718 |
|
|
2020
Q3 | $1.44M | Buy |
18,926
+1,016
| +6% | +$103K | 0.01% | 510 |
|
|
2020
Q2 | $2.21M | Buy |
17,910
+708
| +4% | +$70.4K | 0.01% | 391 |
|
|
2020
Q1 | $1.45M | Sell |
17,202
-51,100
| -75% | -$4.4M | 0.01% | 441 |
|
|
2019
Q4 | $5.78M | Buy |
68,302
+51,687
| +311% | +$3.9M | 0.03% | 224 |
|
|
2019
Q3 | $1.12M | Sell |
16,615
-406
| -2% | -$31.3K | 0.01% | 569 |
|
|
2019
Q2 | $1.46M | Buy |
17,021
+591
| +4% | +$50.6K | 0.01% | 515 |
|
|
2019
Q1 | $1.46M | Sell |
16,430
-332
| -2% | -$30.8K | 0.01% | 502 |
|
|
2018
Q4 | $1.43M | Buy |
16,762
+568
| +4% | +$54K | 0.01% | 456 |
|
|
2018
Q3 | $1.57M | Buy |
16,194
+340
| +2% | +$33.9K | 0.01% | 484 |
|
|
2018
Q2 | $1.49M | Buy |
15,854
+986
| +7% | +$86.3K | 0.01% | 497 |
|
|
2018
Q1 | $1.21M | Buy |
14,868
+155
| +1% | +$13.3K | 0.01% | 533 |
|
|
2017
Q4 | $1.31M | Buy |
14,713
+1,357
| +10% | +$118K | 0.01% | 519 |
|
|
2017
Q3 | $1.24M | Buy |
13,356
+838
| +7% | +$74K | 0.01% | 519 |
|
|
2017
Q2 | $1.14M | Buy |
12,518
+680
| +6% | +$61.9K | 0.01% | 535 |
|
|
2017
Q1 | $1.04M | Buy |
11,838
+43
| +0.4% | +$3.83K | 0.01% | 565 |
|
|
2016
Q4 | $977K | Buy |
11,795
+72
| +0.6% | +$6.19K | 0.01% | 565 |
|
|
2016
Q3 | $1.08M | Buy |
11,723
+56
| +0.5% | +$5.27K | 0.01% | 529 |
|
|
2016
Q2 | $908K | Buy |
11,667
+178
| +2% | +$15.1K | 0.01% | 575 |
|
|
2016
Q1 | $948K | Buy |
11,489
+280
| +2% | +$22.8K | 0.01% | 565 |
|
|
2015
Q4 | $1.17M | Buy |
11,209
+1,190
| +12% | +$124K | 0.01% | 491 |
|
|
2015
Q3 | $1.05M | Buy |
10,019
+3,934
| +65% | +$525K | 0.01% | 509 |
|
|
2015
Q2 | $832K | Buy |
6,085
+203
| +3% | +$25.2K | 0.01% | 595 |
|
|
2015
Q1 | $733K | Buy |
5,882
+262
| +5% | +$27.8K | 0.01% | 629 |
|
|
2014
Q4 | $508K | Buy |
5,620
+169
| +3% | +$14.1K | ﹤0.01% | 688 |
|
|
2014
Q3 | $393K | Buy |
+5,451
| New | +$358K | ﹤0.01% | 754 |
|
|
2014
Q2 | – | Sell |
-5,501
| Closed | -$375K | – | 811 |
|
|
2014
Q1 | $375K | Buy |
+5,501
| New | +$405K | ﹤0.01% | 777 |
|
Other funds holding BMRN
VCM
VPM
CIBC Asset Management's BMRN Position: Q1 2026 in Review
CIBC Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.44% in Q1 2026, selling an estimated $1.52K and leaving 5,927 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #931.
CIBC Asset Management first reported a position in BMRN in Q1 2014 and has held it in 48 quarters since. The position peaked at $5.78M in Q4 2019. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- CIBC Asset Management held 5,927 shares of BioMarin Pharmaceuticals worth $335K as of Q1 2026.
- CIBC Asset Management sold 26 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.52K.
- BioMarin Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #931 holding.
- CIBC Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 48 quarters since.
- CIBC Asset Management's BioMarin Pharmaceuticals position peaked at $5.78M in Q4 2019.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.